Comparative activity of ifosfamide and cyclophosphamide

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Background:

• Cyclophosphamide (CYC) is a widely used alkylating agent in cancer chemotherapy.
• Tumor resistance to CYC presents a significant clinical challenge.
• Ifosfamide (IFO) is a related alkylating agent with a distinct activity profile.

Purpose of the Study:

• To evaluate and compare the antitumor activity of ifosfamide (IFO) versus cyclophosphamide (CYC).
• To assess IFO's efficacy in tumors resistant to CYC and other chemotherapeutic agents.
• To explore IFO's role as a single-agent and combination therapy in various malignancies.

Main Methods:

• Review of experimental tumor models and comparative clinical trials.
• Analysis of IFO activity in CYC-resistant and multi-drug resistant cancer cell lines.
• Evaluation of clinical data from studies investigating IFO in soft tissue sarcoma, ovarian cancer, lymphomas, and lung cancer.

Main Results:

• IFO exhibited greater antitumor activity than CYC in several experimental tumors, including those primarily resistant to CYC.
• IFO demonstrated activity in anthracycline- and cisplatin-resistant tumor sublines.
• Clinical trials suggest superior single-agent activity of IFO over CYC in soft tissue sarcoma and ovarian cancer.
• IFO has shown efficacy in combination chemotherapy for refractory sarcomas, lymphomas, lung, and testicular cancers.

Conclusions:

• Ifosfamide (IFO) is a valuable chemotherapeutic agent with significant activity, particularly in tumors resistant to cyclophosphamide (CYC).
• IFO's lower cross-resistance profile makes it an important option for second-line treatment in various cancers.
• Further comparative clinical trials are warranted to fully define IFO's role in specific malignancies like ovarian, breast, lymphoma, sarcoma, and cervical cancers.